PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C by Petta, S et al.
15 December 2021
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:





(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
This is the author's manuscript
This version is available http://hdl.handle.net/2318/1561140 since 2017-06-01T12:16:50Z
1 
 
Title: PNPLA3 rs738409 I748M Variant and Histological Features of Nonalcoholic 
Steatohepatitis in Patients with Genotype 1 Chronic Hepatitis C 
 
SHORT TITLE:  PNPLA3 AND NASH IN CHRONIC HEPATITIS C 
AUTHORS: Salvatore Petta1, Ester Vanni 3,  Elisabetta Bugianesi 3, Chiara Rosso3 , , 
Daniela Cabibi4, Calogero Cammà1, Vito Di Marco1, Mohammed Eslam2, Stefania 
Grimaudo1, Fabio Salvatore Macaluso1, Duncan McLeod4, Rosaria Maria Pipitone1, Maria 
Lorena Abate 3, , Antonina Smedile3, Jacob George2 and Antonio Craxì 1. 
 
 
INSTITUTONS: 1 Division of Gastroenterology, Di.Bi.M.I.S., University of Palermo, 
Palermo, Italy;
 2 
Storr Liver Unit and 
4
 Institute of Clinical Pathology and Medical 
Research, Westmead Millennium Institute and Westmead Hospital, University of Sydney, 
Australia; 3
 
Division of Gastro-Hepatology, Department of Medical Sciences, San Giovanni 
Battista Hospital, University of Torino, Torino, Italy; 4 Cattedra di Anatomia Patologica, 
University of Palermo, Italy. 
 
ABBREVIATIONS: CHC: chronic hepatitis C; G1: genotype 1;. 
CORRESPONDING AUTHOR: Salvatore Petta, Sezione di Gastroenterologia, University 
of Palermo, Italy,  Piazza delle Cliniche, 2, 90127 Palermo, Italy. Phone: +39 091 655 
2280. Fax +39 091 655 2156. E-mail 1: salvatore.petta@unipa.it; E-mail 2: 
petsa@inwind.it 
TABLES/FIGURES/SUPPORTING DOCUMENTS: 4/2/2 
WORD COUNT: 3032 
CONFLICT OF INTEREST: NONE 




KEY WORDS: PNPLA3, CHC, NASH, STEATOSIS 
Abstract 
Background and Aims: The PNPLA3/Adiponutrin rs738409 C/G single nucleotide 
polymorphism(SNP) is associated with the severity of steatosis, non-alcoholic 
steatohepatitis (NASH) and fibrosis in patients with non-alcoholic fatty liver disease, as 
well as with the severity of steatosis and fibrosis in patients with chronic hepatitis C(CHC). 
We tested in genotype 1(G1) CHC patients the putative association between the PNPLA3 
variant and histological features of NASH, as well as their impact on the severity of 
fibrosis. 
Methods: Four hundred and thirty-four consecutively biopsied Caucasian G1-CHC 
patients were genotyped for the PNPLA3 rs738409. Their metabolic profile included 
assessment of lipid levels and insulin resistance by the homeostasis model 
assessment(HOMA). Histological features of NASH in CHC were assessed using the 
Bedossa classification. Hepatic expression of PNPLA3 mRNA was evaluated in a 
subgroup of 63 patients. 
Results: The prevalence of NASH progressively increased from 16.5% in patients with 
PNPLA3 CC, to 23.2% in CG and 29.2% in GG genotype(p=0.02).  By multiple logistic 
regression PNPLA3 genotype(OR 1.54,95%CI 1.03-2.30,p=0.03) together with age(OR 
1.03,95%CI 1.00-1.05,p=0.02), BMI≥30(OR 2.06,95%CI 1.04-4.10,p=0.03) and HOMA 
(OR 1.18,95%CI 1.04-1.32,p=0.006) was independently linked to histological features of 
NASH. When stratifying for obesity, PNPLA3 was associated with NASH in nonobese 
patients only(12.0% in CC vs 18.3% in CG vs 27.3% in GG, p=0.01), including after 
correction for metabolic confounders(OR 2.06,95%CI 1.26-3.36,p=0.004). We confirmed 
the independent association of rs738409 with the severity of steatosis(OR 1.71,95%CI 
1.20-2.45,p=0.003), and indirectly by promoting steatohepatitis (OR 2.05,95%CI 1.05-
4.02,p=0.003) with severe fibrosis. Higher liver PNPLA3 mRNA was associated both with 
the severity of steatosis(adjusted p=0.03) and steatohepatitis after adjusting for gender, 
age, BMI and HOMA  (p=0.002). 
Conclusions: In Caucasian G1-CHC patients, the PNPLA3 rs738409 G variant is 
associated with a higher risk of both steatosis severity and steatohepatitis in chronic 




The natural history of any chronic liver disease is now known to be modulated by a 
number of emerging risk factors including but not limited to gender, menopausal status, 
age, alcohol intake, fructose consumption, obesity, insulin resistance (IR) and 
hyperuricemia [1,2].  Recent evidence also suggests a key role for the host genetic 
architecture in prompting liver disease occurrence and its severity. In particular, the CG 
rs738409 variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease 
(NAFLD), with the G allele connoting a greater genetic risk [3,4]. The G allele is also 
associated with a higher prevalence of non-alcoholic steatohepatitis (NASH) and 
significant liver fibrosis [5], as well as a greater risk of hepatocellular carcinoma (HCC) in 
NAFLD [5], as validated by two recent meta-analyses [6,7]. 
 When considering the role of PNPLA3 in CHC, similar results were observed. Of 
note some studies on cohorts of mostly genotype 1 (G1) CHC patients reported an 
association between the PNPLA3 rs738409 G variant and the severity of both steatosis 
and fibrosis as well as the risk of HCC occurrence [8-10].Bedossa and colleagues, in liver 
biopsies from CHC patients, recently  characterized the presence of histological features 
of steatohepatitis, showing that the occurrence of NASH in this clinical setting not only was 
related to a poor at-risk metabolic profile, but was also a risk factor for the severity of liver 
damage [11]. This data however did not investigate the impact of genetic background on 
the presence of steatohepatitis in the context of CHC. 
 Hence, the aims of the present study in GH1 CHC patients were to assess the 
putative association between PNPLA3 polymorphism and histological features of 
steatohepatitis, as well as their impact on the severity of liver fibrosis. We are confident 
that the use of the accurate scoring system of Bedossa for steatohepatitis diagnosis in 
CHC, will allow to clarify, first in CHC, the complex interplay among PNPLA3 genotype, 
steatohepatitis, and fibrosis severity. 
 
Patients and Methods 
This cohort study comprised 434 patients with CHC consecutively enrolled in three centers 
(Gastro-hepatology Division of the University Hospital Torino, Italy (n=70), Westmead 
Millenium Institute, Sydney, Australia (n=110) and the Gastrointestinal and Liver Unit of 
the University Hospital Palermo, Italy (n=254) and fulfilling the following inclusion criteria: 
(a) diagnosis of CHC genotype 1 infection based on hepatitis C serology and viral RNA (b) 
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histological diagnosis on liver biopsy, and (c) alcohol consumption <20 g/day in the last 12 
months. Patients were excluded from the study if they were co-infected with either the 
hepatitis B virus or HIV, or if they were not of northern European descent. All participants 
who met the eligibility criteria were recruited after they provided written informed consent.  
Anthropometric and Laboratory Evaluation  
Clinical and anthropometric data were collected at the time of liver biopsy. BMI was 
calculated on the basis of weight in kilograms and height (in meters). Subjects were 
classified as normal weight (BMI, 18.5–24.9 kg/m2), overweight (BMI, 25–29.9) and obese 
(BMI≥30). The diagnosis of type 2 diabetes was based on the revised criteria of the 
American Diabetes Association using a value of fasting blood glucose of ≥126 mg/dl on at 
least two occasions. In patients with a previous diagnosis of type 2 diabetes, current 
therapy with oral hypoglycemic agents was documented.  
Serum levels of total cholesterol, triglycerides and LFTs were determined by routine 
laboratory techniques on the day of liver biopsy. Plasma glucose levels were measured by 
the glucose oxidase method (Beckman Instruments, Fullerton CA; interassay CV 4%). 
Quantitative measurement of insulin in serum was performed using a immunoradiometric 
assay kit (Radim, Pomezia, Italy; interassay CV 13%). IR was determined by the 
homeostasis model assessment (HOMA) method, using the following equation: Insulin 
resistance (HOMA)=Fasting insulin (μU/ml) × Fasting glucose (mmol/L)/22.5 [12].  
Genotyping 
DNA was extracted from peripheral blood collected at the time of enrollment in all 
patients.Genotyping for PNPLA3 (rs738409) was carried out using the TaqMan SNP 
genotyping allelic discrimination method (Applied Biosystems, Foster City, CA, USA). 
Commercial genotyping assays were available for the following SNPs: rs738409 (cat. 
C_7241_10. A custom assay was created by Applied Biosystem for rs12979860. The 
genotyping call was done with SDS software v.1.3.0 (ABI Prism 7500, Foster City, CA, 







Liver biopsy was performed in all patients. Liver histology was used to determine the 
extent of steatosis, hepatic necroinflammation and fibrosis. Steatosis was graded as 
absent/mild (0-10%), moderate (11-29%) or severe (≥30%). Liver fibrosis was classified as 
absent/mild/moderate or severe (bridging fibrosis/cirrhosis), while necroinflammatory 
activity was classified as absent/mild/moderate or severe (based on the degree of 
piecemeal necrosis and lobular necrosis) according to Metavir [13]. According to the 
classification of Bedossa et al [11], histological features of steatohepatitis in CHC were 
also assessed. In particular steatohepatitis was defined according to a score made by the 
addition of clarification/ballooning (0 absent, 1 mild, 2 significant) and perisinusoidal 
fibrosis semiquantitation (0 absent, 1 mild, 2 significant); a score of ≥3 was considered 
diagnostic for steatohepatitis [11]. 
 
Hepatic expression of PNPLA3 mRNA 
Liver samples were stored at-80°C and homogenized using The TissueRuptor aparatus 
(Qiagen) immediately before nucleic acid extraction. DNA, RNA and proteins from biopsy 
or from cells cultures were extracted using the AllPrep DNA/RNA Micro Kit (Qiagen) 
according to the manufacture instructions. A quantity of 0.5µg of RNA was used for cDNA 
synthesis with the QuantiTect Reverse Transcription Kit (Qiagen). The levels of PNPLA3 
mRNA in the samples were determined using a real-time reverse transcription quantitative 
PCR (RT-qPCR) (ABI PRISM 7500 Fast Real Time System, Applied Biosystems). The 
detection was performed using SYBR Green and Quantitect Primer Assays (Qiagen), 
which provide a PCR reaction with high efficiency and specificity. rRNA 18S was used as 
the endogenous control gene. Results were expressed as N-fold difference in target gene 
expression relative to the rRNA 18S gene compared with the expression in the HepG2 cell 
line used as calibrator. Data analysis was performed using Sequence Detection Software 
Version 1.3-7500 from Applied Biosystems. 
 
Statistical Analysis.  
Continuous variables were summarized as mean ± standard deviation, and categorical 
variables as frequency and percentage. The t-test, Chi-square test and ANOVA tests were 
used where appropriate. Multiple logistic regression models were used to assess the 
factors associated with  steatohepatitis and severe fibrosis, while multiple ordinal 
regression model was used to assess variables associated with the severity of steatosis. 
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In the first model, the dependent variable was  steatohepatitis coded as 0 if absent, and as 
1 if present; in the second model, the dependent variable was severe fibrosis, coded as 0 
if absent/mild/moderate, and 1 if bridging fibrosis or cirrhosis; in the third model the 
dependent variable was steatosis classified as 0 if ≤10% (absent/mild), as 1 if from 11% to 
29% (moderate), and as 3 if ≥30% (severe). Input variables included in the models were 
age, gender, BMI, BMI≥30, triglycerides, total- and HDL cholesterol, blood glucose, insulin, 
HOMA score, diabetes, PNPLA3  rs738409 genotype, steatosis, lobular inflammation,  
steatohepatitis and fibrosis. The effect of PNPLA3  rs738409 was evaluated according to 
the  literature by using an additive model [5]. Variables associated with the dependent 
variable on simple logistic/ordinal regression (probability threshold, P < 0.10) were 
included in multiple logistic/ordinal regression. To avoid the effect of co-linearity, HOMA 
score, blood glucose, insulin levels and diabetes, as well as total- and HDL-cholesterol 
were not included in the same model. Regression analyses were done using Proc Logistic, 
Proc Ordinal, Proc t-test, and Proc freq in SAS (SAS Institute, Inc., Cary, North Carolina, 
U.S.A.) [14]. 
 
Patient Features and Histology 
The baseline characteristics of the 434 patients are shown in Supplemental Table 1. The 
mean age was 52 yrs and 46% were female. Obesity and type 2 diabetes were observed 
in about 20% and 10% of patients, respectively. Mean values for total cholesterol, HDL 
cholesterol and triglycerides were within the normal range, while mean HOMA value was 
3.25. One patient in four had severe fibrosis, and one in five had histological features of 
steatohepatitis. 
A minority (9.4%) of patients had the PNPLA3 rs738409 GG polymorphism, compared to 
34.8% and 55.8% with CG and CC variants, respectively. Interestingly, the clinical, 
biochemical and metabolic profile did not differed according to the PNPLA3 genotype 
(Table 1). Instead, the severity of hepatic steatosis (p<0.001) as well as the prevalence of 
histological features of steatohepatitis (p=0.02) progressively increased according to the 




PNPLA3 rs738409 genotype is associated with histological features of 
steatohepatitis and steatosis in G1 CHC patients 
The prevalence of histological features of steatohepatitis progressively increased from 
16.5% in patients with PNPLA3 CC genotype, to 23.2% in CG and further to 29.2% in GG 
(p=0.02) (Figure 1). By simple logistic regression, older age, BMI≥30, higher blood 
glucose, insulin and HOMAHOMA, higher triglycerides, and PNPLA3 G variant were 
associated with histological features of steatohepatitis (p < 0.10) (Table 2). After correction 
for all the above variables, older age (OR 1.03, 95% CI 1.00-1.05,p=0.02), BMI≥30 (OR 
2.06, 95% CI 1.04-4.10,p=0.03), higher HOMA (OR 1.18, 95% CI 1.04-1.32,p=0.006) and 
PNPLA3 G variant (OR 1.54, 95% CI 1.03-2.30,p=0.03) remained significantly associated 
with histological features of steatohepatitis by multivariate logistic regression analysis. 
Considering that both PNPLA3 G variant and BMI≥30  were independently linked to 
histological features of steatohepatitis, we stratified the population according to obesity. As 
expected we found that obese patients had higher metabolic alterations, and a higher 
severity of liver damage in terms of steatosis, fibrosis and histological features of 
steatohepatitis, respect to non obese subjects (Supplemental table 2). Of note, we 
observed that the association between steatohepatitis and the PNPLA3 G variant, was lost 
in obese patients (34.8% in CC vs 38.4% in CG vs 37.5% in GG, p=0.79), while it was 
maintained in non-obese subjects (12.0% in CC vs 18.3% in CG vs 27.3% in GG, p=0.01) 
(Figure 1). Consistent with this data, in non obese subjects steatohepatitis was associated 
with higher HOMA (OR 1.36, 95% CI 1.12-1.66,p=0.002), higher HDL (OR 1.02, 95% CI 
1.00-1.04,p=0.02) and PNPLA3 G variant (OR 2.06, 95% CI 1.26-3.36,p=0.004) by 
multivariate logistic regression analysis. Along this line we observed that while obese 
patients carrying the at high (GG) or at low (CC) risk PNPLA3 genotypes had a similar 
prevalence of steatohepatitis (33.3% vs. 34.9%, p=0.95), different issues were observed in 
nonobese ones. Specifically nonobese patients with PNPLA3 GG genotype had a higher 
prevalence of steatohepatitis compared to their counterpart with PNPLA3 CC (27.2% vs. 
12.0%, p=0.05), that was similar to that of obese  PNPLA3 CC or GG patients (p=0.60, 
and p=0.79, respectively), but was indepentend of insulin resistance assessed by HOMA-
R.   (table 3). 
As previously reported, by ordinal regression analysis we confirmed the association of 
PNPLA3 G variant (OR 1.71, 95% CI 1.20-2.45,p=0.003) with the severity of steatosis, 
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together with BMI≥30  (OR 2.58, 95% CI 1.41-4.72,p=0.002), and higher HOMA (OR 1.22, 
95% CI 1.10-1.35,p<0.001). 
 
Histological features of steatohepatitis are associated with severe hepatic fibrosis 
in CHC  
By simple logistic regression, older age, higher BMI, higher blood glucose, insulin and 
HOMA, lower total and HDL cholesterol, higher triglycerides, severity of steatosis, severe 
necroinflammatory activity and steatohepatitis were associated with severe fibrosis (p < 
0.10) (Table 4). Multiple logistic regression confirmed only older age (OR 1.03, 95% CI 
1.01-1.06,p=0.002), lower total cholesterol (OR 0.98, 95% CI 0.97-0.99, p<0.001), higher 
HOMA (OR 1.18, 95% CI 1.07-1.31,p<0.001), severe necroinflammatory activity (OR 2.16, 
95% CI 1.23-3.79,p=0.007), and steatohepatitis (OR 2.05, 95% CI 1.05-4.02,p=0.003) as 
independent predictors of severe fibrosis (Table 3).  
 Notably, after stratifying for BMI, in the subgroup of nonobese patients 47.1% of 
those with steatohepatitis  had F3-F4 fibrosis compared with 21.2% of those without 
(p<0.001). Along this line steatohepatitis (OR 2.28, 95% CI 1.07-4.85,p=0.03) remained 
significantly associated with F3-F4 fibrosis after correction for metabolic and liver 
confounders. Similar results were observed in the subgroup of obese patients: 57.1% of 
those with steatohepatitis  had severe fibrosis compared with 26.5% of those without 
(adjusted OR 3.77, 95% CI 1.23-11.5,p=0.02) 
 
Hepatic expression of PNPLA3 mRNA 
In a subgroup of 63 patients with available frozen liver samples and with characteristics 
similar to the entire cohort (male 50%, mean age 53.5±9.2 yrs, mean BMI 27.9±5.5 Kg/m2,  
PNPLA3 CC 54.8%, CG 30.7%, GG 14.5%, 25.8% with NASH, and 30.6% with severe 
fibrosis), we assessed the hepatic expression of PNPLA3 mRNA. The expression of 
PNPLA3 was not influenced by PNPLA3 genotype, and was also not associated with 
clinical or biochemical variables (p>0.10 for all) except for older age (p=0.006). A 
significant association was found between liver PNPLA3 expression and the severity of 
steatosis (1.74±0.50 in steatosis absent-mild vs 1.64±0.28 in moderate vs 2.13±0.39 in 
9 
 
severe, p=0.04 by ANOVA), steatohepatitis (1.67±0.46 in no steatohepatitis vs 2.16±0.38 
in steatohepatitis,  p<0.001) (Figure 2), and severe fibrosis (1.71±0.51 in F0-F2 vs 
2.00±0.37 in F3-F4,  p=0.02), even if after correction gender, age, BMI, HOMA, PNPLA3 G 
variant, and steatohepatitis (for fibrosis only), the association was maintained for severe 





In this study we demonstrated that in Caucasian patients with G1 CHC the  PNPLA3 
rs738409 G variant was associated not only with the severity of steatosis, but also with the 
presence of histological features of steatohepatitis. Of particular interest the association 
with steatohepatitis was principally evident in non obese patients that have a lower 
metabolic risk than obese individuals. Hepatic PNPLA3 expression was also correlated 
with both steatosis and steatohepatitis. 
Different lines of evidence have demonstrated that the PNPLA3 rs738409 genotype leads 
to a higher risk of hepatic steatosis [3,4], and among NAFLD patients with a greater risk of 
steatohepatitis and severe fibrosis [5,6]. In CHC, the G allele is also associated with a  
higher risk of steatosis and severe fibrosis [8-10]. 
This study is unique in that we have been able to determine the association between the 
PNPLA3 rs738409 G allele and histological steatohepatitis. This has not been previously 
possible, because of the lack of an objective histological scoring system for steatohepatitis 
in the context of hepatitis C infection. This was achieved in the present study by using the 
well validated score from Bedossa and colleagues [11]. Attesting to the robust nature of 
the score, the association with steatohepatitis was maintained after correction for well-
known metabolic risk factors for NASH like age, obesity, and IR. Furthermore the 
association with histological steatohepatitis persisted after stratification for obesity. Of note 
this association was lost in obese individuals peraphs because metabolic risk factors per 
se overcame the genetic effect of PNPLA3 variant. Instead, the association between 
PNPLA3 variant and steatohepatitis was observed in nonobese patients only, i.e. in those 
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at lower metabolic risk, where the presence of  the PNPLA3 GG prompted a risk of 
steatohepatitis similar to that generated by metabolic factors in obese ones but 
independent of insulin resistance. The stronger effect of PNPLA3 in non obese patients fits 
with a recent study showing that the amount of liver fat is similar in obese NAFLD 
compared to PNPLA3 NAFLD [15],  
Our data confirmed the link reported in CHC between the severity of steatosis and 
PNPLA3 rs738409 variant [8-10], but we were unable to confirm a direct association with 
the severity of fibrosis [8-10]. Differences in clinical, metabolic and histological 
characteristics of studied populations, as well as in the analysis of data could explain the 
different results. Of note our data suggests that PNPLA3 is able to indirectly modulate the 
severity of liver fibrosis by prompting steatohepatitis development. Along this line the 
studies reporting an association between PNPLA3 gene variant and fibrosis in CHC did 
not adjust for steatohepatitis [9], and in some cases neither for steatosis [8,10].  
Our study was unable to demonstrate any association between PNPLA3 rs738409 and 
other metabolic alterations, including IR. These results agree with that already reported in 
G1 CHC patients [8-10], but not with the paper of Rembeck and colleagues [16] observing 
a direct link between PNPLA3 gene variant and both IR and viral load in a small group of 
102 patients with genotype 2 CHC. Instead our data strongly agree with the lack of 
association between PNPLA3 SNP and metabolic variables as showed in large cohort 
studies among NAFLD patients, these data adding strength to the robustness of our 
results [4,17].   
Our cross sectional study was not designed to assess the pathogenic mechanisms linking 
the PNPLA3 genotype to NASH and liver damage in CHC, but a few hypotheses may be 
entertained according to the experimental literature and the data we produced. Wild-type 
PNPLA3 is expressed in hepatocytes and has a lipolytic activity towards triglycerides, 
while the I148M mutation leads to a loss of function [18,19]. Also, the PNPLA3 variant has 
been associated with a hepatocyte gain of lipogenic activity leading to the synthesis of 
phosphatidic acid [20], as well as to a loss of retinyl-palmitate lipase activity in stellate cells 
[21]. When translating this evidence to humans, contrasting and few data exist on the link 
between PNPLA3 liver expression and liver damage. Some study reported no association 
with liver damage in NAFLD [5], some other an inverse link with severity of fibrosis in 
alcoholic liver disease [22], and some other a direct association with severity of steatosis 
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in obese nondiabetic NAFLD [23]. In our study we firstly observed in CHC patients a direct 
link between PNPLA3 mRNA liver expression and both the severity of steatosis and 
steatohepatitis, these associations being maintained after adjusting for metabolic and liver 
confounders. All in all the above quoted data supports clinical evidence about the 
association of PNPLA3 with both steatosis and steatohepatitis, further suggesting that the 
increase of liver PNPLA3 expression could be the response to fatty accumulation – due or 
not due to PNPLA3 variant – and could lead to an increase in pathological functions of 
PNPLA3 – especially in I148M variant-. 
From a clinical point of view our data confirm the role of PNPLA3  rs738409gene variant 
as a major disease modifying factor in CHC that promotes histological steatohepatitis, and 
in turn contributing to the progression of the liver disease. Interestingly our data also 
identified in the non-obese CHC population, i.e. those potentially at lower risk of disease 
progression, the clinical setting in which the hepatic phenotypic effect of PNPLA3 variant is 
strongest and not dominated by metabolic confounders including insulin resistance. All in 
all these data, if prospectically validated, suggest to consider PNPLA3 genotype as a new 
tool for the identification of  nonobese CHC patients worthy of a more intensive follow-up 
while awaiting for the new antiviral drugs. 
The main limitation of this study lies in the potential limited external validity of the results 
for different populations and settings. Thus, replicating our results in other cohorts, is 
important. Lack of data on serum levels of adipocytokines, and on other polymorphisms 
that could conceivably confound the data may have also affected the results.  
In conclusion, we found that in a large cohort of G1 CHC patients, the PNPLA3 rs738409 
G variant is associated with a higher risk of both steatosis severity and steatohepatitis 
especially in non-obese subjects at lower metabolic risk. Hence, these data, if 
prospectically confirmed, could lead to the identification of patients worthy of a careful 
follow-up even after HCV eradication by new direct antiviral agents. We also added new 
pathogenic insides about liver PNPLA3 expression and liver damage, worthy to be 
confirmed and explored by functional studies.  
 
Figure Legends  
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Figure 1. Prevalence of histological features of nonalcoholic steatohepatitis according to 
PNPLA3 genotype in the entire cohort of genotype 1 chronic hepatitis patients and in 
subgroups discriminated according to presence or absence of obesity. 
Figure 2. Liver PNPLA3 mRNA expression in a subgroup of 63 genotype 1 chronic 
hepatitis C patients with or without histological features of nonalcoholic steatohepatitis. P 
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